#Sweden #Stockholm #Sobi #Annual General Meeting #Swedish Orphan Biovitrum

Notice of Annual General Meeting for Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (Sobi®) has officially summoned its shareholders to the Annual General Meeting (AGM) scheduled for May 6, 2026. The meeting will be held at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden, commencing at 10:00 AM. This notice provides crucial information regarding participation, registration, and the proposed agenda for the meeting.

Participation and Registration

To attend the AGM, either in person or by proxy, certain conditions must be met:
1. Shareholders must be listed as such in the Euroclear Sweden AB share register as of April 27, 2026.
2. Notification of participation is required by April 29, 2026, and can be communicated through various methods:
- Online via Euroclear Sweden AB’s website.
- By mail: Swedish Orphan Biovitrum AB (publ), "Annual General Meeting", c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden.
- Email: [email protected].
- Phone: +46 8 402 92 27.

If attending by proxy, a signed power of attorney must be provided. Proxy forms are accessible on Sobi's website. If the shareholder is representing a legal entity, relevant registration documents should also be submitted.

In addition to attending in person, shareholders wishing to exercise their voting rights via postal voting have until April 29, 2026, to send their completed postal voting forms to Euroclear Sweden AB. Instructions for this process are detailed on Sobi's website.

Nominee Registered Shares

Shareholders with shares registered under a nominee must ensure they register their shares in their own name to qualify for voting rights at the AGM.

Proposed Agenda for the Meeting

The scheduled agenda for the AGM will cover the following points:
1. Opening of the Meeting
2. Election of Chair of the Meeting
3. Preparation and approval of the voting list
4. Approval of the agenda
5. Election of individuals to verify the minutes
6. Presentation of financial documents including the annual and auditor's reports
7. Resolutions on profit allocation and discharge of liability for board members
8. Determinations of board fees and election of directors and auditors
9. Presentation and discussion of incentive programs for employees
10. Closing of the Meeting

Key Proposals

Additional noteworthy proposals include resolutions on:

• - Supplemental remuneration programs aimed at management and all employees, promoting adherence to the company’s operational objectives and market conditions. This includes a Management Programme for about 388 key employees and an All Employee Programme open to approximately 1,150 permanent employees.
• - Potential re-elections of board members such as Christophe Bourdon and David Meek, alongside new appointments which may include Mikael Dolsten and Åsa Riisberg.
• - Approval for new share issuances or convertible bonds planned for execution before the next AGM, potentially affecting shareholder dilution, which is anticipated at around 10% if fully executed.

Shareholder Information

Shareholders are invited to request additional information regarding the AGM and may submit related queries prior to the meeting.

Closing Remarks

As a biopharma leader focusing on rare diseases, Sobi remains committed to transparent communication with its stakeholders. This AGM represents an opportunity for stakeholders to engage with management, reflect on the past year, and shape the strategic direction of the company moving forward.

For further information, please refer to Sobi’s official website or their investor relations team.